



COMPANY OVERVIEW

PolarityTE is a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. The PolarityTE platform technology begins with a small piece of the patient's own, or autologous, healthy tissue, rather than artificially manipulated individual cells. From this small piece of healthy autologous tissue, the company creates an easily deployable, dynamic and self-propagating product designed to enhance and stimulate the patient's own cells to regenerate the target tissues. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE manufactures with the patient's own tissue and uses the patient's own body to support the regenerative process to create the same tissue from which it was derived. PolarityTE's innovative method is intended to promote and accelerate growth of the patient's tissues to undergo a form of effective regenerative healing.

RECENT NEWS

PolarityTE to Participate in the 2018 Cantor Fitzgerald Global Healthcare Conference

Sep 20 2018, 8:00 AM EDT

PolarityTE, Inc. Reports Financial Results and Corporate Update for Quarter End July 31, 2018

Sep 12 2018, 7:30 AM EDT

STOCK OVERVIEW

Symbol	PTE
Exchange	Nasdaq
Shares OS	21,475,370
Market Cap	\$464.94M
Last Price	\$21.65
52-Week Range	\$15.21 - \$41.220001

INVESTOR RELATIONS

Rich Haerle
VP of Investor Relations & Corporate Strategy
T: 385-831-5284
ir@polarityte.com

MANAGEMENT TEAM

Denver Lough, M.D., Ph.D.

Chairman of the Board, President, Chief Executive Officer, Chief Scientific Officer

Edward Swanson, M.D.

Executive Vice President & Chief Operating Officer

Paul Mann

Chief Financial Officer

Michael W. Neumeister, MD, FRCSC, FACS

Chief Medical Officer

Cameron Hoyler, J.D.

General Counsel & Executive Vice President, Corporate Development and Strategy

Jennifer Burdman, J.D.

Chief Intellectual Property Officer and Deputy General Counsel

Stephen Milner, MD, BDS, DSc, FRCSE, FACS

Chief Clinical Officer

Maurice Nahabedian, MD, FACS

Chief Surgical Officer

Holly Kramen, J.D.

Chief Compliance Officer and Privacy Officer

POLARITYTE, INC.

1960 S 4250 W
Salt Lake City, UT 84104

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.

